Proxalutamide (developmental code name GT-0918) is a nonsteroidal antiandrogen (NSAA) – specifically, a selective high-affinity silent antagonist of the androgen receptor (AR) – which is under development by Suzhou Kintor Pharmaceuticals, inc., a subsidiary of Kintor Pharmaceutical Limited, for the potential treatment of COVID-19, prostate cancer, and breast cancer.[1][2][3][4][5] It was approved in Paraguay for the treatment of COVID-19 in July 2021, but has not been approved at this time in other countries.[1]
Clinical data | |
---|---|
Other names | Pruxelutamide; GT-0918 |
Routes of administration | By mouth |
Drug class | Nonsteroidal antiandrogen |
ATC code |
|
Identifiers | |
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
Chemical and physical data | |
Formula | C24H19F4N5O2S |
Molar mass | 517.50 g·mol−1 |
3D model (JSmol) |
|
| |
|
Proxalutamide is in phase III studies for mCRPC as monotherapy and in combination with abiraterone. In the United States, it is in phase II study as monotherapy for mCRPC.[6][7]
{{cite journal}}
: Cite journal requires |journal=
(help)